ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease

ClinicalTrials.gov ID: NCT03922711

Public ClinicalTrials.gov record NCT03922711. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 10, 2026, 5:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Randomized, Three-Arm, Parallel-Group Study to Assess the Efficacy and Safety of Two Doses of Pridopidine Versus Placebo for the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease (gLIDe)

Study identification

NCT ID
NCT03922711
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Prilenia
Industry
Enrollment
23 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Pridopidine Drug

Drug

Eligibility (public fields only)

Age range
30 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 21, 2019
Primary completion
Jul 21, 2020
Completion
Jul 21, 2020
Last update posted
Jun 30, 2022

2019 – 2020

United States locations

U.S. sites
33
U.S. states
18
U.S. cities
30
Facility City State ZIP Site status
Prilenia Investigational Site (Site 117) Birmingham Alabama 35233
Prilenia Investigational Site (Site 144) Phoenix Arizona 85004
Prilenia Investigational Site (Site 111) Phoenix Arizona 85013
Prilenia Investigational Site (Site 115) Scottsdale Arizona 85259
Prilenia Investigational Site (Site 106) Fountain Valley California 92708
Prilenia Investigational Site (Site 109) Irvine California 92697
Prilenia Investigational Site (Site 105) Pasadena California 91105
Prilenia Investigational Site (Stie 142) Torrance California 90502
Prilenia Investigational Site (Site 136) Aurora Colorado 80045
Prilenia Investigational Site (Site 135) Englewood Colorado 80113
Prilenia Investigational Site (Site 118) Boca Raton Florida 33431
Prilenia Investigational Site (Site 131) Maitland Florida 32751
Prilenia Investigational Site (Site 122) Sunrise Florida 33351
Prilenia Investigational Site (Site 116) Tampa Florida 33612
Prilenia Investigational Site (Site 138) Atlanta Georgia 30329
Prilenia Investigational Site (Stie 123) Augusta Georgia 30912
Prilenia Investigational Site (Site 107) Iowa City Iowa 52242
Prilenia Investigational Site (Site 102) Kansas City Kansas 66160
Prilenia Investigational Site (Site 126) Omaha Nebraska 68198
Prilenia Investigational Site (Site 141) New Brunswick New Jersey 08901
Prilenia Investigational Site (Site 128) Amherst New York 14226
Prilenia Investigational Site (Site 147) New York New York 10029
Prilenia Investigational Site (Site 101) Raleigh North Carolina 27607
Prilenia Investigational Site (Site 127) Raleigh North Carolina 27612
Prilenia Investigational Site (Site 149) Dayton Ohio 45459
Prilenia Investigational Site (Site 139) Tulsa Oklahoma 74136
Prilenia Investigational Site (Site 114) Philadelphia Pennsylvania 19107
Prilenia Investigational Site (Site 146) Willow Grove Pennsylvania 19090
Prilenia Investigational Site (Site 119) Providence Rhode Island 02903
Prilenia Investigational Site (Site 120) Houston Texas 77030
Prilenia Investigational Site (Site 121) Houston Texas 77030
Prilenia Investigational Site (Site 129) San Antonio Texas 78230
Prilenia Investigational Site (Site 103) Kirkland Washington 98034

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03922711, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 30, 2022 · Synced May 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03922711 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →